v3.23.1
Condensed Consolidated Statements of Earnings (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]    
Net revenues $ 12,225 $ 13,538
Cost of products sold 3,986 4,052
Selling, general and administrative 3,039 3,127
Research and development 2,292 1,497
Acquired IPR&D and milestones 150 145
Other operating income (10) 0
Total operating costs and expenses 9,457 8,821
Operating earnings 2,768 4,717
Interest expense, net 454 539
Net foreign exchange loss 35 25
Other expense (income), net 1,804 (776)
Earnings before income tax expense 475 4,929
Income tax expense 234 436
Net earnings 241 4,493
Net earnings attributable to noncontrolling interest 2 3
Net earnings attributable to AbbVie Inc. $ 239 $ 4,490
Per share data    
Basic earnings per share (in dollars per share) $ 0.13 $ 2.52
Diluted earnings per share (in dollars per share) $ 0.13 $ 2.51
Weighted-average basic shares outstanding (in shares) 1,770 1,771
Weighted-average diluted shares outstanding (in shares) 1,776 1,778